2nd T-Cell Engager for Autoimmune Disease Summit The Colonnade Hotel, Boston

Accelerate the Development of T-Cell Engagers in Autoimmune Diseases by Expanding Targets Beyond B-Cells, Reducing CRS Toxicities, and Achieve Deep Depletion and Clinical Success
The 2nd T-Cell Engager for Autoimmune Disease Summit arrives at a pivotal moment for the field as autoimmune TCEs rapidly transition from oncology-inspired concepts into one of the industry’s most exciting and heavily invested therapeutic modalities. Following major investments and partnerships from companies including Gilead, UCB, Sanofi, and Boehringer Ingelheim, the focus has shifted from proving the modality works to optimizing safety, durability, and clinical differentiation.

As the industry’s only dedicated meeting focused exclusively on autoimmune T-cell engagers, this summit brings together 80+ leaders across discovery, translational, preclinical, clinical, and business development to tackle the field’s most urgent challenges. Discussions will explore how to reduce CRS toxicities, improve tissue-selective immune depletion, engineer next-generation engager architectures, expand beyond B-cell targets, and translate early clinical insights into safer, more effective therapies.

With 15+ new speakers, emerging clinical datasets, 2 deep-dive workshops, and 8+ hours of networking including speed networking and interactive roundtables, this is the must-attend forum to benchmark strategies, build partnerships, and shape the future of autoimmune T-cell engager development.